Colorectal Liver Metastases

Journal of Gastrointestinal Surgery

Volumn 17, Issue 1, 2013, Pages 195-202

  Tzeng, Ching Wei D ^a   Aloia, Thomas A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Chemotherapy associated liver injury; Colon cancer; Colorectal cancer; Hepatectomy; Irinotecan; Liver metastases; Liver resection; Metachronous; Oxaliplatin; Rectal cancer; Reverse approach; Synchronous

Indexed keywords

EID: 84871979885     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-2022-3     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. Jan-Feb 2012; 62(1): 10-29.
2. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. Jun 2002; 235(6): 759-766.
3. Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. Jun 2010; 210(6): 934-941.
4. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. Mar 10 2011; 29(8): 1083-1090.
5. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 3. 2012. 2012; http://www. nccn. org/professionals/physician_gls/pdf/colon. pdf. Accessed July 20, 2012.
6. Child PW, Yan TD, Perera DS, Morris DL. Surveillance-detected hepatic metastases from colorectal cancer had a survival advantage in seven-year follow-up. Dis Colon Rectum. Apr 2005; 48(4): 744-748.
7. Scaife CL, Ng CS, Ellis LM, Vauthey JN, Charnsangavej C, Curley SA. Accuracy of preoperative imaging of hepatic tumors with helical computed tomography. Ann Surg Oncol. Apr 2006; 13(4): 542-546.
8. Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. Apr 2012; 23(4): 948-954.
9. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. Dec 2 2009; 302(21): 2338-2344.
10. Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. Aug 2003; 197(2): 233-241; discussion 241-232.
11. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. Jun 4 1994; 343(8910): 1405-1410.
12. Aloia TA, Vauthey JN. Management of colorectal liver metastases: past, present, and future. Updates Surg. Mar 2011; 63(1): 1-3.
13. Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. Dec 2007; 14(12): 3481-3491.
14. Hillingso JG, Wille-Jorgensen P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer-a systematic review. Colorectal Dis. Jan 2009; 11(1): 3-10.
15. Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH. The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum. Jan 2009; 52(1): 23-30.
16. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. Jul 2006; 93(7): 872-878.
17. Mentha G, Roth AD, Terraz S, et al. 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg. 2008; 25(6): 430-435.
18. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. Jul 10 2009; 27(20): 3379-3384.
19. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. Oct 20 2008; 26(30): 4906-4911.
20. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. Mar 22 2008; 371(9617): 1007-1016.
21. Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. May 2000; 127(5): 512-519.
22. Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. Oct 2009; 250(4): 540-548.
23. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. Nov 2007; 94(11): 1386-1394.
24. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. Nov 2010; 14(11): 1691-1700.
25. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. Jun 1999; 10(6): 663-669.
26. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. Oct 2004; 240(4): 644-657; discussion 657-648.
27. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. Dec 15 2007; 110(12): 2761-2767.
28. Goere D, Gaujoux S, Deschamp F, et al. Patients operated on for initially unresectable colorectal liver metastases with missing metastases experience a favorable long-term outcome. Ann Surg. Jul 2011; 254(1): 114-118.
29. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. Jul 2011; 22(7): 1535-1546.
30. van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. May 20 2011; 29(15): 2011-2019.
31. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. May 2006; 141(5): 460-466; discussion 466-467.
32. Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. Nov 2010; 17(11): 2870-2876.
33. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. Jun 3 2004; 350(23): 2343-2351.
34. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. Jan 15 2004; 22(2): 229-237.
35. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. Feb 8 1990; 322(6): 352-358.
36. Aloia TA, Fahy BN. Chemotherapy-associated hepatotoxicity: how concerned should we be? Expert Rev Anticancer Ther. Apr 2010; 10(4): 521-527.
37. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. May 1 2006; 24(13): 2065-2072.
38. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. Mar 2004; 15(3): 460-466.
39. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. Nov 1 2006; 24(31): 4983-4990.
40. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. Jun 2005; 200(6): 845-853.
41. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. Nov 10 2008; 26(32): 5254-5260.
42. Aloia TA, Fahy BN, Fischer CP, et al. Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford). Sep 2009; 11(6): 510-515.
43. Andres A, Toso C, Moldovan B, et al. Complications of elective liver resections in a center with low mortality: a simple score to predict morbidity. Arch Surg. Nov 2011; 146(11): 1246-1252.
44. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. Jul 2000; 191(1): 38-46.
45. Ito H, Are C, Gonen M, et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. Jun 2008; 247(6): 994-1002.
46. Muratore A, Ribero D, Zimmitti G, Mellano A, Langella S, Capussotti L. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol. May 2010; 17(5): 1324-1329.
47. Figueras J, Burdio F, Ramos E, et al. Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections. Ann Oncol. Jul 2007; 18(7): 1190-1195.
48. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. May 2005; 241(5): 715-722, discussion 722-714.
49. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. Oct 2008; 248(4): 626-637.
50. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. Sep 1999; 230(3): 309-318; discussion 318-321.